Genzyme Corp. (Cambridge, MA) has sued Anika Therapeutics, Inc. (Bedford, MA) for infringement of Patent No. 5,143,724, and 5,399,351 directed to a biocompatible viscoelastic gel slurry and method for using same. In two parts, the complaint specifically targets Anika’s Monovisc® product for treating osteoarthritis.
First, the complaint asserts infringement of the ‘724 patent as a result of the making, using, and offering to sell Monovisc in the U.S. for sale in Europe, Turkey, and Canada. Second, the complaint seeks a declaratory judgment of infringement of the ‘724 and ‘351 patents as Anika gears up to sell Monovisc directly to the U.S. market as demonstrated by a Pre-Market Approval pending before the FDA and other activities.
Genzyme Corp. v. Anika Therapeutics, Inc., 10-11146-NG (D. Mass. July 7, 2010)
Anika claims that Monovisc does not infringe upon the two patents in question. I've read the compaint, and can't tell why it doesn't. Any clue?
Posted by: Faosto | 09/25/2010 at 10:52 PM